OncoDNA

Cancer kills 10 million people every year. Fortunately, the human effort to combat cancer is yielding impressive results. Hundreds of drugs have been approved, thousands of drug trials are ongoing, ten thousand cancer mutations have been discovered, billions of data points all in all. Based on this data, precision oncology enables doctors to choose the most effective treatment for a patient. All these advances are impressive, but they also create a problem - it is too much to digest. Oncologists would have to spend 29 hours per day reading just to stay on top of scientific literature. OncoDNA has developed a powerful decision support system that has significant commercial traction. A perfectly tuned combination of genetic tests, a proprietary database, and reporting tools enable oncologists to find the right personalized approach for every patient, even those for whom everything has failed. Tens of thousands of patient outcomes are fed back into the system, creating valuable new knowledge.
Jean-Pol Detiffe about Verve Ventures
Verve Ventures brings us a network of interesting private investors that have strong connections to big healthcare companies in the pharma and biotech space.
Founders / Management Jean-Pol Detiffe
Sectors Health & Bio, Oncology, Theranostics
Located in Belgium, Spain
Co-Investors Vesalius Biocapital Partners, Sambrinvest, Ackermans & van Haaren, CPH Banque, Inventures, Swisscanto, SFPI-FPIM, Future Capital
Follow On

LinkedIn

Sign up to receive our weekly newsletter and learn about investing in technologies that are changing the world.